BRMS1L
Breast cancer metastasis-suppressor 1-like protein
Also known as: BRM1L_HUMAN, BRMS1, FLJ39177, MGC11296
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5PSV4
- Gene
- BRMS1L
- Ensembl
- ENSG00000100916
- Chromosome
- 14
- Canonical length
- 323 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
The protein encoded by this gene shows sequence similarity to the human breast carcinoma metastasis suppressor (BRMS1) protein and the mammalian Sds3 (suppressor of defective silencing 3) proteins. This protein is a component of the mSin3a family of histone deacetylase complexes (HDAC). [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
323 residues, UniProt reviewed canonical sequence.
>Q5PSV4|BRMS1L
1 MPVHSRGDKK ETNHHDEMEV DYAENEGSSS EDEDTESSSV SEDGDSSEMD DEDCERRRME
61 CLDEMSNLEK QFTDLKDQLY KERLSQVDAK LQEVIAGKAP EYLEPLATLQ ENMQIRTKVA
121 GIYRELCLES VKNKYECEIQ ASRQHCESEK LLLYDTVQSE LEEKIRRLEE DRHSIDITSE
181 LWNDELQSRK KRKDPFSPDK KKPVVVSGPY IVYMLQDLDI LEDWTTIRKA MATLGPHRVK
241 TEPPVKLEKH LHSARSEEGR LYYDGEWYIR GQTICIDKKD ECPTSAVITT INHDEVWFKR
301 PDGSKSKLYI SQLQKGKYSI KHSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BRMS1L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.51
- Highest tissue expression
- 14 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 14 nTPM
- tongue: 13 nTPM
- skeletal muscle: 13 nTPM
- heart muscle: 11 nTPM
- amygdala: 10 nTPM
- adrenal gland: 9.5 nTPM
Single-cell type
- salivary myoepithelial cells: 68 nCPM
- thymic myoid cells: 53 nCPM
- medullary thymic epithelial cells: 48 nCPM
- vascular smooth muscle cells: 46 nCPM
- lactotrophs: 43 nCPM
- myonuclei: 41 nCPM
Immune cell
- naive CD4 T-cell: 1.4 nTPM
- non-classical monocyte: 1.4 nTPM
- T-reg: 1.4 nTPM
- memory CD8 T-cell: 1.3 nTPM
- intermediate monocyte: 1.2 nTPM
- naive CD8 T-cell: 1.2 nTPM
Brain region
- white matter: 16 nTPM
- basal ganglia: 15 nTPM
- cerebral cortex: 15 nTPM
- midbrain: 13 nTPM
- thalamus: 13 nTPM
- pons: 13 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.58
- gnomAD pLI
- 0.06
- gnomAD missense Z
- 2.15
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of cell migration
- negative regulation of stem cell population maintenance
- negative regulation of transcription by RNA polymerase II
- negative regulation of transforming growth factor beta receptor signaling pathway
- positive regulation of stem cell population maintenance
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of BRMS1L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BRMS1L as an antibody target. Whether an autoantibody or antibody against BRMS1L could matter depends on whether native BRMS1L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BRMS1L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label BRMS1L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...